This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
All content for MedEdicus Podcasts is the property of MedEdicus and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
(CME Podcast) Improving Outcomes in Patients with Geographic Atrophy: Cases in Clinical Practice - Part 2
MedEdicus Podcasts
28 minutes
8 months ago
(CME Podcast) Improving Outcomes in Patients with Geographic Atrophy: Cases in Clinical Practice - Part 2
In part 2 of our podcast series on geographic atrophy, Dr. Lejla Vajzovic and Dr. Arshad Khanani will do a deep dive into current treatment options to optimize patient outcomes. Listeners will be enabled to develop treatment plans for patients with geographic atrophy through a review of clinical study data, case scenarios, and real-world cases. This comprehensive session will empower listeners to confidently assess and manage geographic atrophy in their practice.
MedEdicus Podcasts
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
